THSD4-AS1: A Potential Drug Target and Biomarker (G101929196)

Target Name: THSD4-AS1

NCBI ID: G101929196

THSD4-AS1

Other Name(s): THSD4 antisense RNA 1, transcript variant 4 | THSD4 antisense RNA 1, transcript variant 3 | THSD4 antisense RNA 1 | THSD4 antisense RNA 1, transcript variant 2 | THSD4 antisense RNA 1, transcript variant 1

THSD4-AS1: A Potential Drug Target and Biomarker

THSD4-AS1, also known as THSD4 antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug or biomarker has led to a growing interest in the field of RNA-based therapeutics.

THSD4-AS1 is a small non-coding RNA molecule that is expressed in various tissues and cells throughout the body. It is characterized by a head domain that contains a conserved core sequence and a tail domain that includes a unique N-terminal and C-terminal region. The head domain is responsible for the stability and translation of the molecule into the cytoplasm, while the tail domain is involved in the molecule's stability and interactions with other molecules.

THSD4-AS1 has been shown to play a role in several diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that high levels of THSD4-AS1 are associated with poor prognosis in several types of cancer, including breast, ovarian, and colorectal cancers. Additionally, THSD4-AS1 has been shown to be involved in several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its association with disease, THSD4-AS1 has also been shown to have potential as a drug or biomarker. For example, studies have shown that inhibiting THSD4-AS1 can significantly reduce the progression of neurodegenerative diseases, including Alzheimer's disease, in animal models. Additionally, THSD4-AS1 has been shown to be a potential biomarker for several diseases, including cancer and neurodegenerative diseases.

The unique structure and function of THSD4-AS1 have made it an attractive target for researchers to investigate. By studying its function and potential as a drug or biomarker, researchers may be able to develop new treatments for a variety of diseases. As research continues to advance, the potential of THSD4-AS1 as a drug or biomarker will be further understood, and its role in the treatment of various diseases will continue to grow.

In conclusion, THSD4-AS1 is a non-coding RNA molecule that has been shown to play a role in several diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug or biomarker has led to a growing interest in the field of RNA-based therapeutics. Further research is needed to fully understand the role of THSD4-AS1 in disease and its potential as a treatment.

Protein Name: THSD4 Antisense RNA 1

The "THSD4-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about THSD4-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets